FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297263539> ?p ?o ?g. }

• W4297263539 abstract "This study aims to provide an overview of outcomes after right ventricular outflow tract (RVOT) reconstruction using different valve substitutes in different age groups for different indications.The literature was systematically searched for articles published between January 2000 and June 2021 reporting on clinical and/or echocardiographic outcomes after RVOT reconstruction with valve substitutes. A random-effects meta-analysis was conducted for outcomes, and time-related outcomes were visualized by pooled Kaplan-Meier curves. Subgroup analyses were performed according to etiology, implanted valve substitute and patient age.Two hundred and seventeen articles were included, comprising 37,078 patients (age: 22.86 ± 11.29 years; 31.6% female) and 240,581 patient-years of follow-up. Aortic valve disease (Ross procedure, 46.6%) and Tetralogy of Fallot (TOF, 27.0%) were the two main underlying etiologies. Homograft and xenograft accounted for 83.7 and 32.6% of the overall valve substitutes, respectively. The early mortality, late mortality, reintervention and endocarditis rates were 3.36% (2.91-3.88), 0.72%/y (95% CI: 0.62-0.82), 2.62%/y (95% CI: 2.28-3.00), and 0.38%/y (95%CI: 0.31-0.47) for all patients. The early mortality for TOF and truncus arteriosus (TA) were 1.95% (1.31-2.90) and 10.67% (7.79-14.61). Pooled late mortality and reintervention rate were 0.59%/y (0.39-0.89), 1.41%/y (0.87-2.27), and 1.20%/y (0.74-1.94), 10.15%/y (7.42-13.90) for TOF and TA, respectively. Endocarditis rate was 0.21%/y (95% CI: 0.16-0.27) for a homograft substitute and 0.80%/y (95%CI: 0.60-1.09) for a xenograft substitute. Reintervention rate for infants, children and adults was 8.80%/y (95% CI: 6.49-11.95), 4.75%/y (95% CI: 3.67-6.14), and 0.72%/y (95% CI: 0.36-1.42), respectively.This study shows RVOT reconstruction with valve substitutes can be performed with acceptable mortality and morbidity rates for most patients. Reinterventions after RVOT reconstruction with valve substitutes are inevitable for most patients in their life-time, emphasizing the necessity of life-long follow-up and multidisciplinary care. Follow-up protocols should be tailored to individual patients because patients with different etiologies, ages, and implanted valve substitutes have different rates of mortality and morbidity.[www.crd.york.ac.uk/prospero], identifier [CRD42021271622]." @default.
• W4297263539 created "2022-09-28" @default.
• W4297263539 creator A5001356671 @default.
• W4297263539 creator A5001970800 @default.
• W4297263539 creator A5034795892 @default.
• W4297263539 creator A5042300012 @default.
• W4297263539 creator A5045847080 @default.
• W4297263539 creator A5052643047 @default.
• W4297263539 creator A5056101043 @default.
• W4297263539 creator A5068677288 @default.
• W4297263539 creator A5080670496 @default.
• W4297263539 date "2022-09-07" @default.
• W4297263539 modified "2023-10-01" @default.
• W4297263539 title "Outcomes after right ventricular outflow tract reconstruction with valve substitutes: A systematic review and meta-analysis" @default.
• W4297263539 cites W1534181333 @default.
• W4297263539 cites W1979540882 @default.
• W4297263539 cites W1982967337 @default.
• W4297263539 cites W2010018275 @default.
• W4297263539 cites W2036740 @default.
• W4297263539 cites W2039084354 @default.
• W4297263539 cites W2040339824 @default.
• W4297263539 cites W2054747465 @default.
• W4297263539 cites W2082353019 @default.
• W4297263539 cites W2100098441 @default.
• W4297263539 cites W2101073837 @default.
• W4297263539 cites W2102922451 @default.
• W4297263539 cites W2109887283 @default.
• W4297263539 cites W2113018842 @default.
• W4297263539 cites W2127577244 @default.
• W4297263539 cites W2130239397 @default.
• W4297263539 cites W2130874836 @default.
• W4297263539 cites W2131965385 @default.
• W4297263539 cites W2142984767 @default.
• W4297263539 cites W2148768650 @default.
• W4297263539 cites W2154799508 @default.
• W4297263539 cites W2159691158 @default.
• W4297263539 cites W2161374186 @default.
• W4297263539 cites W2164269479 @default.
• W4297263539 cites W2170892587 @default.
• W4297263539 cites W2173472004 @default.
• W4297263539 cites W2212678910 @default.
• W4297263539 cites W2275358554 @default.
• W4297263539 cites W2501206009 @default.
• W4297263539 cites W2531628199 @default.
• W4297263539 cites W2593749802 @default.
• W4297263539 cites W2614689855 @default.
• W4297263539 cites W2722049029 @default.
• W4297263539 cites W2736227559 @default.
• W4297263539 cites W2798033129 @default.
• W4297263539 cites W2904274696 @default.
• W4297263539 cites W2912236149 @default.
• W4297263539 cites W2922446843 @default.
• W4297263539 cites W2925942064 @default.
• W4297263539 cites W3010093973 @default.
• W4297263539 cites W3016961654 @default.
• W4297263539 cites W3079743398 @default.
• W4297263539 cites W3081668292 @default.
• W4297263539 cites W3135648333 @default.
• W4297263539 cites W3172673791 @default.
• W4297263539 cites W3186417870 @default.
• W4297263539 cites W4206001728 @default.
• W4297263539 cites W896293506 @default.
• W4297263539 doi "https://doi.org/10.3389/fcvm.2022.897946" @default.
• W4297263539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36158811" @default.
• W4297263539 hasPublicationYear "2022" @default.
• W4297263539 type Work @default.
• W4297263539 citedByCount "4" @default.
• W4297263539 countsByYear W42972635392023 @default.
• W4297263539 crossrefType "journal-article" @default.
• W4297263539 hasAuthorship W4297263539A5001356671 @default.
• W4297263539 hasAuthorship W4297263539A5001970800 @default.
• W4297263539 hasAuthorship W4297263539A5034795892 @default.
• W4297263539 hasAuthorship W4297263539A5042300012 @default.
• W4297263539 hasAuthorship W4297263539A5045847080 @default.
• W4297263539 hasAuthorship W4297263539A5052643047 @default.
• W4297263539 hasAuthorship W4297263539A5056101043 @default.
• W4297263539 hasAuthorship W4297263539A5068677288 @default.
• W4297263539 hasAuthorship W4297263539A5080670496 @default.
• W4297263539 hasBestOaLocation W42972635391 @default.
• W4297263539 hasConcept C126322002 @default.
• W4297263539 hasConcept C137627325 @default.
• W4297263539 hasConcept C141071460 @default.
• W4297263539 hasConcept C164705383 @default.
• W4297263539 hasConcept C179755657 @default.
• W4297263539 hasConcept C2775872228 @default.
• W4297263539 hasConcept C2777361368 @default.
• W4297263539 hasConcept C2778646171 @default.
• W4297263539 hasConcept C2780074459 @default.
• W4297263539 hasConcept C2780298129 @default.
• W4297263539 hasConcept C2780714102 @default.
• W4297263539 hasConcept C71924100 @default.
• W4297263539 hasConcept C95190672 @default.
• W4297263539 hasConceptScore W4297263539C126322002 @default.
• W4297263539 hasConceptScore W4297263539C137627325 @default.
• W4297263539 hasConceptScore W4297263539C141071460 @default.
• W4297263539 hasConceptScore W4297263539C164705383 @default.
• W4297263539 hasConceptScore W4297263539C179755657 @default.
• W4297263539 hasConceptScore W4297263539C2775872228 @default.
• W4297263539 hasConceptScore W4297263539C2777361368 @default.
• W4297263539 hasConceptScore W4297263539C2778646171 @default.

• next